An interventional study of White LED light and Green LED light in Ehlers-Danlos Syndrome and Pain, Chronic, sponsored by New York Institute of Technology. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-06.
Sponsored by New York Institute of Technology · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Ehlers-Danlos Syndrome with a site in United States — 9 open to participants now, 11 under way, none of them phase 3. Ehlers-Danlos Syndrome · United States.
Among the 26 studies in Ehlers-Danlos Syndrome with a site in United States, this one is the 11th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is one of 13 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 16th registered.
67 studies on the registry are indexed under Ehlers-Danlos Syndrome; 24 are open to participants now.
Browse Ehlers-Danlos Syndrome studies →9 of the 26 studies in Ehlers-Danlos Syndrome with a site in United States are open now. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18+
Integrative Skin Science and Research · Sites in United States
Ages 18+ · Women only · Healthy volunteers
xCures · Sites in United States
Integrative Skin Science and Research · Sites in United States
Ages 35–70 · Women only · Healthy volunteers
Brain Inflammation Collaborative · Sites in United States
Ages 2+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Ehlers-Danlos Syndrome studies recruiting now, 9 (75%) set no upper age limit and 3 (25%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 30 is below the median of 60 across 32 interventional studies indexed under Ehlers-Danlos Syndrome.
Median enrollment 60 across the 15 interventional studies, 334 across the 11 observational. Of the 15 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 26 have an industry lead sponsor. The 10 most frequent:
New York Institute of Technology is the lead sponsor of 60 studies on the registry; 16 are open to participants now.
New York Institute of Technology has 1 study filed under Ehlers-Danlos Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Ehlers-Danlos Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07464093Brigham and Women's HospitalSTABLE Pilates for Hypermobility | 2026-12 |
| NCT07743229Medical University of South CarolinaCOG+OT Telerehabilitation for Adults With Subjective Cognitive Complaints | 2027-07-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Ehlers-Danlos Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic pain is a major complaint among many individuals living with hypermobile Ehlers Danlos Syndrome (hEDS) and may have a severe impact on quality of life and activities of daily living. Given the complexity of the disease's pathophysiology, effective treatments are limited. This investigation will examine the impacts of green light exposure on subject-reported pain severity and symptoms. Knowing whether this intervention can improve pain and quality of life in this population may offer valuable guidance to clinicians who treat hEDS patients and to hEDS patients themselves.
Chronic pain is a major complaint among many individuals living with hEDS and may have a severe impact on quality of life and activities of daily living. Given the complexity of the disease's pathophysiology, effective treatments are limited. A multidisciplinary approach, including pharmacologic and nonpharmacologic pain management, physical therapy, occupational therapy, and psychological treatment alongside prophylactic care and interventions has been recommended for these patients. The application of light for pain and injury has been studied for some time. More recently, specific colored light has shown promise in treating chronic pain. Green light emitting diodes significantly reduced the number of headache days in people with episodic migraine or chronic migraine. Additionally, green light emitting diodes significantly improved multiple secondary outcome measures including quality of life and intensity and duration of the headache attacks. As no adverse events were reported, green light emitting diodes may provide a treatment option for those patients who prefer non-pharmacological therapies or may be considered in complementing other treatment strategies. This investigation will examine the impacts of green light exposure on subject-reported pain severity and symptoms. Knowing whether this intervention can improve pain and quality of life in this population may offer valuable guidance to clinicians who treat hEDS patients and to hEDS patients themselves.
Subjects will be enrolled for a total of 10 weeks, inclusive of either a 10-week control white light exposure period or a 10-week experimental green light exposure period. Central sensitization inventory will be used to determine the degree of central sensitization contributing to pain for each subject at baseline.
All subjects will be provided with a light source that will achieve light intensity of 4 and 100 lux measured at approximately 1 and 2 meters from point of exposure from a lux meter to determine the illuminance and luminous emittance of the LED strips. Subjects will be free to change the distance of the light source between 1 and 2 meters from their eyes to find the intensity that best suited them. The equipment will be provided during the initial clinic visit or mailed to the patients' homes and they will be instructed to use it in a dark room with no other source of light, except provided source, for a minimum of 1 hour every day, with the option to increase the exposure time to 2 hours daily for 10 weeks. The subjects will be asked to eliminate other sources of extraneous light (no use of televisions, computers, or smartphones; curtains drawn and existing room lights turned off) and will be encouraged to keep their eyes open, to blink at a normal rate, and not to stare directly at the light source. Subjects will be encouraged to engage in any activity while undergoing light exposure, such as reading or listening to music, and avoid falling asleep. Subjects will have the option to receive a daily text message/email reminder about light exposure and questionnaire completion. They will be provided with questionnaires to document the primary and secondary outcomes. Subjects will be allowed to continue their current medical therapy as recommended by their treating physicians. They will also be allowed to start any new medications as recommended by their treating physicians and instructed to document all medications used for their pain. Subjects will self-report the light exposure log, pain medication log, and pain severity data daily to minimize the chances of recall bias. Short-Form McGill Pain Questionnaire (SFMPQ) will be self-reported by subjects every 2 weeks. Short-Form 36 Health Survey (SF-36) data will be self-reported by subjects at their initial visit, 5-week visit, and 10-week visit. Athens Insomnia Scale (AIS) and Test My Brain (TMB) cognitive performance measures will be completed at baseline and week 10. The daily log and McGill Short-Form will be completed on paper. Other measures will be set up electronically for ease of patient completion and submission, but paper evaluations will be available as a back-up if there are technological difficulties. The TMB cognitive performance tests are performed on a computerized interactive interface and patients will be given access to the activities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Exposure to white LED light for 1-2 hours/day x 10 weeks
Device: White LED light
Exposure to green LED light for 1-2 hours/day x 10 weeks
Device: Green LED light
Exposure to white LED light for 1-2 hours/day x 10 weeks
Exposure to green LED light for 1-2 hours/day x 10 weeks
Changes in pain intensity as measured by subject-reported numeric pain severity (NPS) rating
Subjects will report pain intensity daily as a numeric pain severity (NPS) rating, a subjective pain scale ranging from 0 (no pain) to 10 (most severe pain)
Time frame: 10 weeks
Qualitative changes in pain as measured by Short-Form McGill Pain Questionnaire (SFMPQ)
Subjects will describe pain per Short-Form McGill Pain Questionnaire (SFMPQ) every 2 weeks through the duration of their participation. In this questionnaire, subjects will rate their pain on scales from 0 (no pain) to 3 (severe pain). Higher scores indicate worse outcomes.
Time frame: 10 weeks
Changes in frequency of pain medication usage
Subjects will report frequency of any pain medications used through the duration of their participation
Time frame: 10 weeks
Changes in dosage of pain medication used
Subjects will report dosages of any pain medications used through the duration of their participation
Time frame: 10 weeks
Health-related quality of life as measured by subject-reported Short-Form 36 Health Survey (SF-36)
Subjects will complete Short-Form 36 Health Survey (SF-36) at baseline, week 5, and week 10. This survey asks subjects to qualitatively rate their health-related limitations of activities of daily living on Likert scales (e.g. ranging from "no limitation" to "severe limitation").
Time frame: 10 weeks
Insomnia as measured by subject-reported Athens Insomnia Scale
Subjects will complete Athens Insomnia Scale at baseline and week 10. Subjects will rate aspects of their sleep quality on this scale from 0 (no problem) to 3 (severe problem).
Time frame: 10 weeks
Verbal memory as measured by "Test My Brain" (TMB) digital neuropsychiatry cognitive performance test
Subjects will complete "Test My Brain" (TMB) digital neuropsychiatry cognitive performance test assessing verbal memory at baseline and week 10. This computerized test calculates the subject's performance in learning and recognizing sets of word pairs. Performance is digitally analyzed, quantified and compared against normative data by age, gender and education level. Higher scores are associated with improved outcomes.
Time frame: 10 weeks
Sustained attention as measured by "Test My Brain" (TMB) digital neuropsychiatry cognitive performance test
Subjects will complete "Test My Brain" (TMB) digital neuropsychiatry cognitive performance test assessing sustained attention at baseline and week 10. This computerized test calculates the subject's performance in recognizing and responding to sets of rapidly transitioning images. Performance is digitally analyzed, quantified and compared against normative data by age, gender and education level. Higher scores are associated with improved outcomes.
Time frame: 10 weeks
Plan to share: No
Started Nov 2022 (actual). Primary completion is estimated for Nov 2025, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
New York Institute of Technology